Visceral fat appears to be associated with an increased risk of musculoskeletal and widespread pain, according to researchers writing this week in Arthritis and Rheumatology. Plus, a small study shows promise in a new treatment for a rare form of pediatric lupus. This and more news in today's rheumatology news roundup.
In patients with moderate to severe systemic lupus erythematosus (SLE), anifrolumab (AstraZeneca) was superior to placebo for improving overall disease activity, skin disease and oral corticosteroid tapering, say researchers writing in the New England Journal of Medicine.
Anifrolumab, a potential new treatment for systemic lupus erythematosus (SLE), was given a second look in a clinical trial published in the New England Journal of Medicine this month. This time, the results look promising. Learn more about the trial in this slideshow.
In this slideshow, we feature the lupus stories that resonated most with our readers in 2019: Lupus patients are increasingly turning to opioid use to control pain, a study that shows anifrolumab may be the next belimumab for lupus, patients are turning to pill splitting to keep costs down, among others.
Nearly one third of patients with systemic lupus erythematosus use prescription opioids, with around two thirds of those using opioids for more than a year, while emergency department use is associated with increased prescription opioid use, say researchers writing in Morbidity and Mortality Weekly Report in Septmeber.
2019 was a significant year for new developments in the treatment of systemic lupus. These include new treatment options for systemic lupus and updated treatment guidelines for established treatments. In this slideshow, we highlight a few of the achievements made throughout the year.
A large proportion of patients with systemic lupus erythematosus (SLE) have been inappropriately prescribed opioids, researchers reported recently in the Morbidity and Mortality Weekly Report.
ACR Annual Meeting: In patients with moderate to severe systemic lupus erythematosus, anifrolumab (AstraZeneca) was superior to placebo for overall disease activity, skin disease and oral corticosteroid tapering, among other efficacy endpoints, according to a study presented at the annual meeting of the American College of Rheumatology in Atlanta on November 12.
ACR Annual Meeting: At the American College of Rheumatology annual meeting in Atlanta today, Dr. Konstantinos Tselios of the University of Toronto addresses the challenges associated with developing new treatments for systemic lupus.
Availability of new dosages for hydroxychloroquine—a first-line therapy for systemic lupus—may be best for patients, shows a survey conducted by the Lupus Foundation of America.